Panacea Biotec Shares Surge 4.03% to ₹432 After Securing $35.65 Million UNICEF Vaccine Supply Contract

Mumbai, 6 October 2025: Panacea Biotec Ltd (NSE: PANACEABIO, BSE: 531349) share price witnessed a 4.03% gain, reaching ₹432 as of 1:24 p.m. IST, following the announcement of a major contract with the United Nations International Children’s Emergency Fund (UNICEF) to supply bivalent oral polio vaccine (bOPV) valued at approximately US$ 35.65 million (₹315 crore) for Q2 CY2026 and CY2027.

Founded in 1984 and listed since April 17, 1996, Panacea Biotec Ltd is headquartered in New Delhi. Operating in the pharmaceuticals and biotechnology sectors, the company specialises in vaccines, biosimilars, and branded generics, with exports to over 30 countries. The UNICEF contract is expected to further consolidate Panacea Biotec’s position as a reliable international vaccine supplier, enhancing its visibility in the global immunisation market.

Panacea Biotec Secures Long-Term UNICEF Supply Agreement Worth $35.65 Million

In a filing dated 3 October 2025, Panacea Biotec confirmed receipt of a Letter of Award from UNICEF for a Long-Term Agreement (LTA) to supply bOPV in 10 and 20 vial presentations from April 1, 2026 to March 31, 2030. This international contract reinforces the company’s position as a key global vaccine supplier, with UNICEF expected to provide further details on the supplier, vaccine specifications, duration, total value, and annual pricing per presentation.

Stock Performance Reacts to International Contract With Intra-Day High of ₹454

The announcement triggered a notable uptick in Panacea Biotec’s shares, which opened at ₹417.50, touched a high of ₹454.00, and a low of ₹415.95, with a traded volume of 4.32 lakh shares and a volume-weighted average price (VWAP) of ₹439.46. The company’s market capitalisation stands at ₹2,650 crore, reflecting its growing significance in the pharmaceuticals sector. Year-on-year, the stock remains below its 52-week high of ₹581.90 but well above its 52-week low of ₹271.20, demonstrating stable growth amid a competitive global vaccine market.

The UNICEF agreement underscores Panacea Biotec’s capacity to secure long-term international contracts, highlighting operational scale, production capabilities, and global outreach. This development reflects a significant step in the company’s strategic expansion within the global vaccines sector, reinforcing its presence as a trusted supplier in international healthcare initiatives.

REF: https://nsearchives.nseindia.com/corporate/PANACEABIO_03102025142516_ReceiptofawardfromUnicef03102025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations